Activation of the brain 5-HT2C receptors causes hypolocomotion without anxiogenic-like cardiovascular adjustments in mice

Oliver Stiedl, Ilga Misane, Melanie Koch, Tommy Pattij, Michael Meyer, Sven Ove Ögren, M. Meijer, S.O. Ogren

Research output: Contribution to journalArticleAcademicpeer-review

29 Citations (Scopus)


The present study evaluated whether hypolocomotion elicited by subcutaneous administration of the non-specific 5-HT/preferential 5-HT2C receptor agonist mCPP during novelty exposure was due to an enhanced anxiety-like state. The effects of mCPP on exploratory behavior during exposure to a new environment (novelty) were studied in male C57BL/6N mice. Subcutaneous injection of mCPP (1 and 3 mg/kg) and the preferential 5-HT2C receptor agonist MK212 (0.7 and 1 mg/kg) induced hypolocomotion during novelty exposure. The selective 5-HT2C receptor antagonist SB242084 (0.3 mg/kg) reversed the mCPP-induced hypolocomotion into hyperlocomotion. In contrast, MK212 induced hypolocomotion that was blocked by SB242084, indicating a specific 5-HT2C receptor involvement. When injected intracerebroventricularly, mCPP (30 μg) elicited hypolocomotion, whereas the same dose mildly increased locomotion when injected into the dorsal hippocampus. Since anxiety affects autonomic functions, effects of mCPP on cardiovascular function were studied by radio-telemetry in the home cage of unrestrained mice. Subcutaneous injection of mCPP (3 mg/kg) had no significant effect on heart rate and mean arterial blood pressure. In summary, in view of lack of autonomic effects, and the lack of hypoactivity upon forebrain stimulation, the hypolocomotion induced by systemic mCPP cannot be explained by an enhanced anxiety-like state.

Original languageEnglish
Pages (from-to)949-957
Number of pages9
Issue number3
Publication statusPublished - Mar 2007


  • Blood pressure
  • Fear conditioning
  • Heart rate
  • Hippocampus
  • Novelty
  • mCPP

Cite this